Compare Amylx Pharmaceuticals Inc (AMLX) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Clear Secure Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Clear Secure Inc trades at $55.25 (market cap $5.56B). The key difference: Clear Secure Inc is far larger — about 2.8× Amylx Pharmaceuticals Inc's market cap, and Clear Secure Inc pays a 1.09% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | YOU | |
|---|---|---|
Market Cap | $1.98B | $5.56B |
Sector | Health | Technology |
52-Week High | $18.70 | $62.36 |
52-Week Low | $7.64 | $28.38 |
Enterprise Value | $1.70B | $4.88B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Clear Secure (YOU) trades at $55.22, down 1.6% on the day, with a bullish technical signal from moving averages and strong fundamental growth. Recent earnings beat expectations in Q1 2026, and the company expanded services with AWS integration and new airport launches. Revenue reached $900.78M in 2025, with net income of $109.17M and robust cash flow from operations of $372.45M.
Outlook remains positive due to earnings momentum and strategic expansions, but risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $56.67 price target, suggesting moderate upside potential from current levels amid balanced sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
